Open access

851 Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4–1BB x 5T4 ADAPTIR™ bispecific antibody
Michelle Nelson, Robert Miller, Anneli Nilsson, Lill Ljung, Allison Chunyk, Catherine McMahan, David Bienvenue, Maria Askmyr, Gabriela Hernandez-Hoyos, Sara Fritzell

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A507; DOI: 10.1136/jitc-2020-SITC2020.0851
852 Differential expression of surface protein-encoding genes highlights therapeutic vulnerabilities of four SCLC subtypes
Elizabeth Park, Carl Gay, C Allison Stewart, Kasey Cargill, Lixia Diao, Qi Wang, Robert Cardnell, Jing Wang, John Heymach, Lauren Byers

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A507-A508; DOI: 10.1136/jitc-2020-SITC2020.0852
854 Prediction of severe immune-related adverse events in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the United States
Mark Kalinich, William Murphy, Shannon Wongvibulsin, Vartan Pahalyants, Kun-Hsing Yu, Feicheng Wang, Leyre Zubiri, Vivek Naranbhai, Alexander Gusev, Shawn Kwatra, Kerry Reynolds, Yevgeniy Semenov

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A508-A509; DOI: 10.1136/jitc-2020-SITC2020.0854
82 SQ3370 is a novel approach that decreases adverse drug exposure and achieves robust injected and non-injected anti-tumor responses
Sangeetha Srinivasan, Nathan Yee, Kui Wu, Amir Mahmoodi, Michael Zakharian, Maksim Royzen, Jose Mejia Oneto

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A51-A52; DOI: 10.1136/jitc-2020-SITC2020.0082
856 Preliminary review of Diabetes Mellitus incidence in patients treated with immune checkpoint inhibitors (ICI) therapy – Roswell Park Comprehensive Cancer Center (RPCCC) experience
Zhen Zhang, Grazyna Riebandt, Rajeev Sharma, Lamya Hamad, Jordan Scott, Laurie Plewinski

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A510; DOI: 10.1136/jitc-2020-SITC2020.0856
858 A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies
Peter Ellmark, Karin Hägerbrand, Mattias Levin, Laura Von Schantz, Adnan Deronic, Laura Varas, Anna Säll, Karin Barchan, Doreen Werchau, Lill Ljug, Mia Thageson, Anna Rosen, Christina Sakellariou, Malin Lindstedt, Peter Ellmark

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A511; DOI: 10.1136/jitc-2020-SITC2020.0858
859 Inhibition of the kinase activity of hematopoietic progenitor kinase 1 enhances anti-PD-1-induced reinvigoration of human tumor-infiltrating CD8+ T cells
Yongjoon Lee, Seung Hyuck Jeon, A Yeong Park, Suyeon Jo, Jinhwa Lee, Su-Hyung Park, Jamie Jae Eun Kim, Eui-Cheol Shin

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A511-A512; DOI: 10.1136/jitc-2020-SITC2020.0859
860 Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer
Anita Mehta, Emily Cheney, Christina Hartl, Constantia Pantelidou, Madison Oliwa, Jessica Castrillon, Jia-Ren Lin, Katie Hurst, Mateus de Oliveira Taveira, Nathan Johnson, William Oldham, Marian Kalocsay, Matthew Berberich, Sarah Boswell, Aditi Kothari, Shawn Johnson, Deborah Dillon, Mikel Lipschitz, Scott Rodig, Sandro Santagata, Judy Garber, Nadine Tung, José Yélamos, Jessica Thaxton, Elizabeth Mittendorf, Peter Sorger, Geoffrey Shapiro, Jennifer Guerriero

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A512; DOI: 10.1136/jitc-2020-SITC2020.0860
862 Targeting PSGL-1, a novel macrophage checkpoint, repolarizes suppressive macrophages, induces an inflammatory tumor microenvironment, and suppresses tumor growth
Phuong Nguyen, Ryan Phennicie, Kevin Kauffman, Dominika Nowakowska, Mohammad Zafari, Veronica Komoroski, Steve Sazinsky, Joe Wahle, Denise Manfra, Shantashri Vaidya, Michael Brehm, Igor Feldman, Tatiana Novobrantseva

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A513; DOI: 10.1136/jitc-2020-SITC2020.0862
863 Identification and characterization of an immunodominant SARS-CoV-2-specific CD8 T cell response
Anastasia Gangaev, Pia Kvistborg

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A513-A514; DOI: 10.1136/jitc-2020-SITC2020.0863

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages